Elevated PAI-1 levels are associated with insulin resistance, endothelial dysfunction, liver fibrosis, and elevated cardiovascular risk, making this inhibitor a key systemic indicator of metabolic derangement [6]. The gene discussed is SERPINE1; the disease is endothelial dysfunction.